Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Continued use of trastuzumab beyond disease progression in the national comprehensive cancer network: should we practice ahead of the evidence?

Authors
Type
Published Article
Journal
The Oncologist
1549-490X
Publisher
Alphamed Press
Publication Date
Volume
16
Issue
5
Pages
559–565
Identifiers
DOI: 10.1634/theoncologist.2010-0360
PMID: 21450786
Source
Medline
License
Unknown

Abstract

Prior to the availability of any high-quality evidence supporting this practice, over three quarters of patients treated with trastuzumab for HER-2+ metastatic breast cancer at eight NCCN centers continued therapy beyond progression. Further work is needed to understand how physicians adopt new treatments when there is ambiguity surrounding their benefit.

Statistics

Seen <100 times